Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

APACMed: Riding The Tailwind Of Health Care And Medtech Through The Pandemic And Beyond

COVID-19 has not put the brakes on the resurgence of health care, say Asia-based VC investors

Executive Summary

VC investors and medtech strategists alike at APACMed’s 2020 virtual conference agreed that the challenges presented by COVID-19 have given healthtech a higher profile and accelerated the arrival of health system workflow improvements.

You may also be interested in...



UK Updates Guidance To Reflect EU Medtech Extensions - Pledges Focus On Agility, Innovation

The EU’s decision to extend the Medical Device Regulation transition periods for legacy medical device directives products will be mirrored in the UK, which also continues to evolve its post-Brexit medtech regulatory system.

Switzerland’s Swift Reaction To MDR’s Extended Transitions Keeps EU Equivalency

The medtech regulatory authorities in Switzerland have pledged to follow the EU’s lead in granting extended transition periods for legacy devices under the MDR.

Pivotal Opportunity For UK Medtech Must Not Be Wasted

The UK continues to work on its new medtech regulatory system and market access processes for innovations, but all the planning and preparations will count for little if not accompanied by sound execution, warns Lincoln Tsang of law firm Ropes & Gray.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT142879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel